Matri Pharmaceuticals India Profile
Key Indicators
- Authorised Capital ₹ 0.20 M
as on 22-12-2024
- Paid Up Capital ₹ 0.20 M
as on 22-12-2024
- Company Age 10 Year, 6 Months
- Last Filing with ROC 31 Mar 2024
- Revenue 0.06%
(FY 2022)
- Profit -56.23%
(FY 2022)
- Ebitda 59.29%
(FY 2022)
- Net Worth 5.19%
(FY 2022)
- Total Assets -41.45%
(FY 2022)
About Matri Pharmaceuticals India
The Corporate was formerly known as Shiuli Infracon India Private Limited. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.20 M and a paid-up capital of Rs 0.20 M, as per Ministry of Corporate Affairs (MCA) records.
Khuku Sahoo and Kartic Sahoo serve as directors at the Company.
- CIN/LLPIN
U45400WB2014PTC202037
- Company No.
202037
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
05 Jun 2014
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Kolkata
Industry
Company Details
- Location
24 Parganas, West Bengal, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Matri Pharmaceuticals India?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Khuku Sahoo  | Director | 01-Dec-2018 | Current |
| Kartic Sahoo | Director | 05-Jun-2014 | Current |
Financial Performance of Matri Pharmaceuticals India.
Matri Pharmaceuticals India Private Limited, for the financial year ended 2022, experienced modest growth in revenue, with a 0.06% increase. The company also saw a substantial fall in profitability, with a 56.23% decrease in profit. The company's net worth moved up by a moderate rise of 5.19%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Matri Pharmaceuticals India?
In 2019, Matri Pharmaceuticals India had a promoter holding of 100.00%. The company had 2 Associate Companies. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Matri Infracon Projects India Private LimitedActive 10 years 6 monthsKhuku Sahoo and Kartic Sahoo are mutual person
- Sagnika Global Marketing Private LimitedActive 5 years 5 months
Khuku Sahoo and Kartic Sahoo are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Matri Pharmaceuticals India?
Unlock and access historical data on people associated with Matri Pharmaceuticals India, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Matri Pharmaceuticals India, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Matri Pharmaceuticals India's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
